{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Moran J"],"funding":["MSc Translational Oncology","Deans Research Initiative Award","Trinity College Dublin"],"pagination":["360"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9959685"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(2)"],"pubmed_abstract":["Glioblastoma multiforme (GBM) is the most common adult primary brain malignancy, with dismal survival rates of ~14.6 months. The current standard-of-care consists of surgical resection and chemoradiotherapy, however the treatment response is limited by factors such as tumour heterogeneity, treatment resistance, the blood-brain barrier, and immunosuppression. Several immunotherapies have undergone clinical development for GBM but demonstrated inadequate efficacy, yet future combinatorial approaches are likely to hold more promise. Olaparib is FDA-approved for BRCA-mutated advanced ovarian and breast cancer, and clinical studies have revealed its utility as a safe and efficacious radio- and chemo-sensitiser in GBM. The ability of Olaparib to enhance natural killer (NK) cell-mediated response"],"journal":["Pharmaceutics"],"pubmed_title":["Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses."],"pmcid":["PMC9959685"],"funding_grant_id":["N/A"],"pubmed_authors":["Dev KK","Marion C","Conroy MJ","Keenan E","O'Sullivan J","Kane LE","Moran J","Mylod E","Mekhaeil M","Lysaght J"],"additional_accession":[]},"is_claimable":false,"name":"Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses.","description":"Glioblastoma multiforme (GBM) is the most common adult primary brain malignancy, with dismal survival rates of ~14.6 months. The current standard-of-care consists of surgical resection and chemoradiotherapy, however the treatment response is limited by factors such as tumour heterogeneity, treatment resistance, the blood-brain barrier, and immunosuppression. Several immunotherapies have undergone clinical development for GBM but demonstrated inadequate efficacy, yet future combinatorial approaches are likely to hold more promise. Olaparib is FDA-approved for BRCA-mutated advanced ovarian and breast cancer, and clinical studies have revealed its utility as a safe and efficacious radio- and chemo-sensitiser in GBM. The ability of Olaparib to enhance natural killer (NK) cell-mediated response","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-04-08T14:36:30.091Z","creation":"2024-11-20T08:07:05.855Z"},"accession":"S-EPMC9959685","cross_references":{"pubmed":["36839682"],"doi":["10.3390/pharmaceutics15020360"]}}